PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015, New Report Launched
PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015 report analyses that PD-1 and PD-L1 inhibitors are among the highly targeted mechanisms in oncology. There are 34 drugs are in pipeline. Out of 34 drugs, 22 are in combinations with other therapeutics agents. Focus of development is mainly on the antibody-based interventions targeting programmed cell death protein 1 (PD-1) and Programmed death-ligand 1 (PD-L1). Continuation of expansion of the combination regimens is likely to be one of...
View full press release